FIG A4.

Overlay of Kaplan-Meier curves from this study (V600, red line; non-V600, blue line) and from Combi-D study (Novartis; V600E/K, green line) for orientating comparison of survival outcomes of rare BRAF mutations compared to V600E/K: (A,C) Kaplan Meier estimates for BRAFi/MEKi combination; (B,D) BRAFi monotherapy. Clinical outcome of patients with rare BRAF mutations appeared inferior to patients with BRAF V600E/K mutations. For overall survival (OS) it has to be noted that Combi-D allowed for cross-over to BRAFi/MEKi combination after progression on BRAFi monotherapy. PFS, progression-free survival.